AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$LUNG

French Glendon E. III sold $95K of LUNG

French Glendon E. III (President and CEO) sold 41,882 shares of Pulmonx Corp (LUNG) at $2.26 across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · French Glendon E. III
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

Small insider sale with limited market impact.

02

Market read

Routine insider transaction; minimal trading relevance.

03

What to watch

Large remaining stake (1.14M shares) suggests continued confidence.

Relevance 3/10Novelty 4/10Timing: filed Sep 3, 2026

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

President and CEO Glendon E. French sold 41,882 shares for $94.7K on Sep 1, 2026.

Expected impact

Likely negligible price effect given low transaction size.

Evidence & confidence

Sale represents ~3.7% of insider holdings; typical for liquidity, not a red flag.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not imply negative outlook.

Key entities

  • Company
    Pulmonx Corp

    Medical device company (ticker LUNG).

  • Executive
    Glendon E. French

    President and CEO of Pulmonx Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LUNG insider trading history →

Related articles

JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 29
$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon

SEC EDGAR 8-K3 min